Non-executive Director Remuneration

ABCAM PLC

("Abcam" or "the Company")

Non-executive Director Remuneration

Abcam announces that pursuant to a new Non-Executive Director ("NED") fee agreement entered into today between the Company and each of the NEDs, part of their fees will be delivered as a fixed number of Abcam shares.

For Abcam's financial year ending 30 June 2016 and thereafter, one third of NED initial total fees will be delivered as fully paid ordinary shares of the Company ("Shares"). A fixed number of Shares will be calculated for each NED by dividing one third of total fees by the average share price of £5.95 (being the average Share price for the ten dealing days following the announcement of Abcam's preliminary results for the year ended 30 June 2015).

A net number of Shares, which will be acquired in the market, will be delivered annually following the announcement of Abcam's preliminary results each year, and after normal PAYE and National Insurance deductions. Each of the NEDs has committed not to transfer or sell the Shares during the term of their non-executive directorship.

The fee agreement will continue until the year ended 30 June 2018, when it will be reviewed.

Murray Hennessy, Chairman, said "Each of Abcam's Non-Executive Directors is committed to their role and guiding the development of the business. Having part of our fees delivered as Abcam shares is a clear demonstration of support for Abcam's strategy and the alignment of NED interests with those of shareholders."

For further information please contact:

Notes to Editors

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com